Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Current Assets: 2009-2025

Historic Current Assets for Aytu Biopharma (AYTU) over the last 16 years, with Sep 2025 value amounting to $81.1 million.

  • Aytu Biopharma's Current Assets rose 33.54% to $81.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.1 million, marking a year-over-year increase of 33.54%. This contributed to the annual value of $79.2 million for FY2025, which is 27.93% up from last year.
  • Aytu Biopharma's Current Assets amounted to $81.1 million in Q3 2025, which was up 2.44% from $79.2 million recorded in Q2 2025.
  • Aytu Biopharma's Current Assets' 5-year high stood at $105.2 million during Q2 2021, with a 5-year trough of $59.9 million in Q2 2022.
  • Moreover, its 3-year median value for Current Assets was $71.4 million (2023), whereas its average is $71.2 million.
  • As far as peak fluctuations go, Aytu Biopharma's Current Assets spiked by 39.53% in 2021, and later crashed by 43.05% in 2022.
  • Over the past 5 years, Aytu Biopharma's Current Assets (Quarterly) stood at $87.5 million in 2021, then declined by 19.34% to $70.6 million in 2022, then rose by 1.08% to $71.4 million in 2023, then dropped by 11.65% to $63.1 million in 2024, then skyrocketed by 33.54% to $81.1 million in 2025.
  • Its last three reported values are $81.1 million in Q3 2025, $79.2 million for Q2 2025, and $72.5 million during Q1 2025.